SCHEMBL648019

SCHEMBL648019

CCCCn1c(-c2ccccc2OC)nc(C(F)(F)F)c1CN(Cc1ccc(SC)cc1)Cc1ccc2c(c1)OCO2

nearest known ligand 0.44

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
C5AR1 P21730 1/20 0.44
F2R P25116 2/20 0.39
HTR2A P28223 4/20 0.38
HTR2B P41595 4/20 0.38
HTR2C P28335 3/20 0.38
LMNA P02545 1/20 0.37
SMN1; SMN2 Q16637 1/20 0.37
L3MBTL1 Q9Y468 1/20 0.37
TP53 P04637 3/20 0.35
ADRA1D P25100 1/20 0.34
ADRA1A P35348 1/20 0.34
ADRA1B P35368 1/20 0.34
POLB P06746 1/20 0.34
HSP90AA1 P07900 1/20 0.34
HSP90AB1 P08238 1/20 0.34
UBE2M P61081 2/20 0.34
DCUN1D1 Q96GG9 2/20 0.34
HTR7 P34969 1/20 0.34
ALDH1A1 P00352 1/20 0.34
NPSR1 Q6W5P4 1/20 0.34

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL649407 0.94 C5AR1 (0.49) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL1913040 0.89 C5AR1 (0.43) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL647851 0.89 C5AR1 (0.44) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL648571 0.88 C5AR1 (0.42) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL649515 0.87 C5AR1 (0.43) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL14572862 0.86 DRD2 (0.34) HTR2BHTR2CLMNAHTR7ALDH1A1
SCHEMBL651654 0.86 C5AR1 (0.42) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL651675 0.86 HTR2A (0.42) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL653205 0.86 C5AR1 (0.42) C5AR1F2RHTR2AHTR2BHTR2C
SCHEMBL651130 0.84 CRHR1 (0.33) HTR2BHTR2CLMNAALDH1A1

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 12 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
EP-2097385-B1 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2012-08-01 EP disclosed
US-8119681-B2 2-[1-phenyl-5-hydroxy or methoxy-4alpha-methyl-hexahydrocyclopenta [ƒ]indazole-5-YL]ethyl phenyl derivatives as glucocorticoid receptor ligands MERCK SHARP & DOHME CORP. (US) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
US-8119665-B2 Aryl imidazoles and related compounds as C5a receptor modulators NOVARTIS INTERNATIONAL PHARMACEUTICAL LTD. (BM) 2012-02-21 US disclosed
EP-2091922-B1 2-[1-PHENYL-5-HYDROXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA[F]INDAZOL-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME (US) 2011-12-21 EP disclosed
US-20100311709-A1 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS MERCK SHARP & DOHME CORP. 2010-12-09 US disclosed
US-20100228036-A1 PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS CHEN QINGHAO 2010-09-09 US disclosed
EP-1490044-A4 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORP (US) 2008-04-16 EP disclosed
US-7186734-B2 Aryl imidazoles and related compounds as C5a receptor modulators NEUROGEN CORPORATION (US) 2007-03-06 US disclosed
EP-1490044-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2004-12-29 EP disclosed
WO-2003084524-A1 COMBINATION THERAPY FOR THE TREATMENT OF CONDITIONS WITH PATHOGENIC INFLAMMATORY COMPONENTS NEUROGEN CORPORATION (US) 2003-10-16 WO disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20100228036-A1 PROCESS FOR MAKING GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, GRK4 C5AR1 146/4885F2R 292/4885HTR2A 1127/4885
US-20100311709-A1 2-[1-PHENYL-5-HYDROXY OR METHOXY-4ALPHA-METHYL-HEXAHYDROCYCLOPENTA [f]INDAZOLE-5-YL]ETHYL PHENYL DERIVATIVES AS GLUCOCORTICOID RECEPTOR LIGANDS NR3C1, NR3C2, NR5A1 C5AR1 86/4885F2R 391/4885HTR2A 649/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.